Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Cantor Fitzgerald

Equities researchers at Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) in a report released on Tuesday, Marketbeat reports. The brokerage set an "overweight" rating and a $695.00 price target on the biopharmaceutical company's stock. Cantor Fitzgerald's target price would suggest a potential upside of 15.33% from the stock's previous close. Cantor Fitzgerald also issued estimates for Regeneron Pharmaceuticals' FY2025 earnings at $26.38 EPS.

Several other research firms have also recently weighed in on REGN. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday, March 31st. Citigroup cut their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $945.32.

Regeneron Pharmaceuticals Trading Up 0.5 %

REGN traded up $2.88 during midday trading on Tuesday, reaching $602.64. 964,377 shares of the company's stock traded hands, compared to its average volume of 723,778. Regeneron Pharmaceuticals has a 52 week low of $525.99 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a fifty day moving average of $637.38 and a two-hundred day moving average of $725.82. The stock has a market capitalization of $65.88 billion, a price-to-earnings ratio of 15.74, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the previous year, the business posted $11.86 earnings per share. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $25,000. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the period. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $28,000. E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the period. Finally, Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.